Pharvaris Outlines 2026 Strategic Priorities, Confirms NDA Filing and Key Phase 3 Data Timelines

summarizeSummary

Pharvaris N.V. detailed its 2026 strategic priorities, confirming the NDA filing for on-demand HAE treatment in 1H2026 and anticipating pivotal Phase 3 data for prophylactic HAE treatment in 3Q2026, supported by a cash runway into 1H2027.

check_boxKey Events

• NDA Filing on Track

  The company expects to file its U.S. New Drug Application (NDA) for deucrictibant as an on-demand treatment for HAE attacks in the first half of 2026, following positive results from the RAPIDe-3 Phase 3 study.

• Pivotal Phase 3 Data Anticipated

  Topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant for prophylactic treatment of HAE attacks is expected in the third quarter of 2026.

• AAE-C1INH Study Progress

  Recruitment is ongoing in the CREAATE pivotal Phase 3 study for deucrictibant in both prophylactic and on-demand treatment of AAE-C1INH attacks.

• Financial Runway

  Pharvaris estimates its cash runway will extend into the first half of 2027, providing capital to advance its late-stage clinical programs.

auto_awesomeAnalysis

Pharvaris N.V. provided a comprehensive update on its 2026 strategic priorities, highlighting significant progress in its deucrictibant development programs for hereditary angioedema (HAE) and acquired angioedema (AAE-C1INH). The company confirmed its New Drug Application (NDA) filing for on-demand HAE treatment is on track for the first half of 2026, following positive Phase 3 RAPIDe-3 results. Additionally, topline data from the pivotal CHAPTER-3 study for prophylactic HAE treatment is anticipated in the third quarter of 2026. These milestones are critical for the company's future commercialization efforts and represent major value inflection points. The estimated cash runway into the first half of 2027 provides financial stability to execute these plans.